Globally, bladder cancer (BCa) is the tenth most common cancer, the sixth most common among men, and the ninth leading cause of cancer death, with four‐fold higher risk in males compared with females. Incidence rates are normally higher in industrialized countries, and are much lower in developing countries, with very few exceptions, such as in Lebanon and Egypt.
Arylamines, major BCa environmental and occupational risk factors, are mainly metabolized by the genetically polymorphic N‐acetyltransferases 1, NAT1 and NAT2.
In this study, FHS researchers joined efforts with peers from the Faculty of Medicine in the American University of Beirut and Saint George hospital to investigate the association between N‐acetyltransferases genetic polymorphism and key MIBC and NMIBC tumor biomarkers and subtypes.
Read the full study HERE.